Formulation of Ramipril Tablets Containing Solid Dispersion Employing Selective Polymers to Enhance Dissolution Rate
Objective: The present work based on formulation of Ramipril tablets containing solid dispersion employing selective polymers. The objective of the preparation is to prepare the solid dispersion of the Ramipril, which has more responsive value in terms of the dissolution rate.
Method: Solid dispersion complex was prepared with two different carriers PEG 6000 and PVP K30. Nine formulations were developed and each formulation were subjected to pre compression and post compression parameters.
Result and Discussion: Pre-compression and post compression parameters were studied which had shown good flow property and compiled the standard data. In-vitro dissolution studies shows more than 90 % drug release in phosphate buffer pH 6.8 in 30 min. Out of all formulation F4 showed 92.55±0.67 % drug release with in 30min which was the best result rest of the formulation.
Conclusion: Ramipril tablets were successfully prepared and evaluated. F4 formulation shows the greater dissolution rate in phosphate buffer pH 6.8 as compared to other formulations. When compared with marketed formulation it also shows better results. Therefore, Ramipril solid dispersion tablets enhanced the dissolution rate and can be more efficacious for improving oral bioavailability of Ramipril.
Keywords: Solid dispersion, Ramipril, Solvent Evaporation Technique.
2. Manogna K, Nagaveni P, Thyagaraju K. Enhancement of solubility of poorly soluble drugs by solid dispersion: An overview. Ind. Journal of Pharmaceutical and Biological Research. 2017; 5:17-23.
3. Fischer, Jnos Ganellin, C Robin. Analogue-based Drug Discovery. John Wiley & amp; Sons. 2006; 469.
4. British national formulary: BNF. Pharmaceutical Press. 2018; 76:172–173.
5. Hilal Dandan R, Goodman Gilmans. The Pharmacological Basis of Therapeutics. McGraw-Hill Education. 2018; 13:26.
6. Frampton JE, Peters DH. Ramipril An updated review of its therapeutic use in essential hypertension and heart failure. Drugs. 1995; 49(3):440–66.
7. Ali J, Khar R, Ahuja A. A textbook of dosage form design. Birla publications Pvt Ltd, Delhi. 3rd edition. 2008; 100-107.
8. Pandey A, Rath B, AK D. Pharmaceutical Preformulation Studies with Special Emphasis on Excipients Compatibility. Chem Inform. 2012; 43(23): 20-5.
9. KP Sampath Kumar, Debjit Bhowmik, Rajnish Kumar Singh. Formulation and evaluation of Ramipril transdermal patch. IAJPR. 2014; 4(4):1850-1856
10. George SJ, Vasudevan DT. Studies on the preparation, characterization and solubility of 2-HP-β-cyclodextrin-Meclizine HCl inclusion complexes. JYP. 2012; 4(4):220-227.
11. Peixiao T, Shanshan Li, Wang L, Yang H, Yan J, Hui L. Inclusion complexes of chlorzoxazone with β- and hydroxypropyl-β-cyclodextrin: Characterization, dissolution,and cytotoxicity. Carbo. Poly 131. 2015:297–305
12. B Venkateswara Reddy, K Navaneetha. Formulation and evaluation of sustain release tablets of Ramipril. Pharmatutor. 2014; 2(7):110-119.
13. Swati CJ, Yashwant TD, Bhanudas SK. Solubility enhancement and formulation of buccal patches of ramipril cyclodextrin complex. Asian J Pharm Clin Res. 2013; 6(2):83-90.
14. Venugopal P, Gnanaprakash K, Kumar B, Gobinath M, Narendra RB. Development of formulation and evaluation of Ramipril porous tablet by sublimation technique. IJB. 2014; 5(4):258-264.
15. Bhusnure OG, Kazi P, Gholve SB, S, Thonte SS, Sangshetti JN. Formulation and Evaluation of Fast Disintegrating Tables of Nifedipine by QbD Approach. IJPPR. 2015; 4(3):198-229.
16. Pradhan R, Tran TH, Choi JY, Choi IS, Choi HG, Yong CS, et al. Development of a rebamipide solid dispersion system with improved dissolution and oral bioavailability. Arch. Pharm. Res. 2014: 1-12.
17. Jumbarathi SK, Chandrasekhara RB, Kavati R, Vanitha PK. Formulation and evaluation of bilayer floating tablets of atorvastatin and ramipril. IAJPS. 2014; 1(2):98-106.
18. Manjil P, Tekade A, Gattani S, Surana S. Solubility enhancement of lovastatin by modified locust bean gum using solid dispersion techniques. Pharm Sci Tech. 2008; 9(4):1262-1269.
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported License. that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).